Arvinas, Inc.
ARVNDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ARVN Earnings Report
EPS Est: $-0.24 | FQ end 2026-06
How ARVN's past catalysts played out
Anastrozole
Breast Cancer
ARV-471
Breast Cancer
ARV-110
Prostate Cancer Metastatic
ARV-806
KRAS G12D Mutation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Anastrozole | Phase 2 | Breast Cancer | - | |
ARV-471 | Phase 2 | Breast Cancer | - | - |
ARV-110 | Phase 2 | Prostate Cancer Metastatic | - | - |
ARV-806 | Phase 2 | KRAS G12D Mutation | - | - |
Breast Cancer
2 drugs in this indication
KRAS G12D Mutation
1 drug in this indication
Prostate Cancer Metastatic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Arvinas, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Arvinas, Inc.'s (ARVN) pipeline across Phase 2. Its lead program is Anastrozole (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arvinas, Inc.'s next FDA catalyst?→
Arvinas, Inc.'s (ARVN) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARVN biotech catalysts?→
Add ARVN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arvinas, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.